Publications by authors named "Elizabeth Albuquerque"
Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
Front Immunol
October 2019
Article Synopsis
- The article DOI: 10.3389/fimmu.2019.01211 has been revised or corrected to address previous errors or updates.
- The correction may include adjustments to data, conclusions, or experimental methods to enhance the accuracy of the original findings.
- Readers are encouraged to refer to the corrected version for reliable information and insights presented in the research.
Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
Front Immunol
October 2020
Article Synopsis
- The study investigates whether immunity from a specific yellow fever vaccine is maintained 8 years after using subdoses in 98 volunteers, comparing them to non-vaccinated controls.
- The findings show that those who received lower doses still had similar levels of neutralizing antibodies and T-cell memory compared to those who got the full dose, particularly for doses above a certain level.
- Strong correlations were found between different immune cell types, indicating effective immune response and supporting the idea that lower vaccine doses can still provide adequate protection.
Article Synopsis
- In 2009, Bio-Manguinhos conducted a study on yellow fever vaccine dosage, finding that doses as low as 587 IU maintained similar immune responses to the full dose, while lower doses (158 IU and 31 IU) were less effective.
- The current study, assessing long-term seropositivity eight years post-vaccination, found that 85% of participants retained immunity, promoting the use of fractional doses during outbreaks.
- The research supports the World Health Organization's minimum recommended vaccine dose of 1000 IU for effective immunity.
Background: Several countries have used pegylation technology to improve the pharmacokinetic properties of essential drugs. Recently, a novel interferon alfa-2b protein conjugated to four-branched 12 kDa polyethylene glycol molecules was developed jointly between Cuba and Brazil. The aim of this study was to compare the pharmacokinetic properties of BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil) to those of PEGASYS® (commercially available pegylated interferon alfa-2a from Roche Pharmaceutical).
View Article and Find Full Text PDFImmunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study.
Contemp Clin Trials
March 2015
This study aimed to determine if immunogenicity to measles-mumps-rubella vaccine delivered to infants via a disposable-syringe jet injector (DSJI) was non-inferior to that administered by needle and syringe (NS). Vaccination safety was evaluated, as were the use, performance, and acceptability of each delivery method. The DSJI was the PharmaJet 2009 generation-1 device (G1) and the vaccine was measles-mumps-rubella vaccine from Bio-Manguinhos.
View Article and Find Full Text PDFBackground: : There are few studies on HIV subtypes and primary and secondary antiretroviral drug resistance (ADR) in community-recruited samples in Brazil. We analyzed HIV clade diversity and prevalence of mutations associated with ADR in men who have sex with men in all five regions of Brazil.
Methods: : Using respondent-driven sampling, we recruited 3515 men who have sex with men in nine cities: 299 (9.
Introduction: The aim of this study was to evaluate the reliability of self-reported HIV among men who have sex with men (MSM) in Brazil.
Methods: MSM 18 years of age or older were recruited to a multicenter study using respondent-driven sampling. We compared self-report of the HIV test with a rapid HIV test using the kappa coefficient.
Putting respondent-driven sampling on the map: insights from Rio de Janeiro, Brazil.
J Acquir Immune Defic Syndr
August 2011
Background: Hard-to-reach populations with high background infection rates for HIV are particularly relevant in countries with restricted HIV epidemics, such as Brazil, where the very dynamics of the epidemic depends on the bridges between those populations and the general population. Respondent-driven sampling (RDS) has been one of the key strategies to assess such populations and inform policy making.
Objectives: To geocode and visualize an RDS-based study on 605 heavy drug users, conducted in Rio de Janeiro, in 2009.
A beta-glucuronidase was purified from Pomacea sp. eggs by ammonium sulfate fractionation, DEAE-BioGel and Heparin-Sepharose chromatographies. This enzyme showed a Mr 180 kDa, with subunits of 90 kDa.
View Article and Find Full Text PDF